Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluciclovine PET/CT for Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048Phase 1Recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Apr 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in brain metastases, sponsored by Baptist Health South Florida. Primary endpoints: Change in sensitivity for PET/CT at 1 year, Change in sensitivity for MRI at 1 year and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT04689048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689048.